| Product Name | HIF1a ELISA kit (Rat) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Hypoxia Inducible Factor 1 Alpha (HIF1a). No significant cross-reactivity or interference between Hypoxia Inducible Factor 1 Alpha (HIF1a) and analogues was observed. |
| Synonyms | HIF1-A; MOP1; PASD8; Basic Helix-Loop-Helix Transcription Factor; ARNT-interacting protein; Basic-helix-loop-helix-PAS protein MOP1; Class E basic helix-loop-helix protein 78 |
| Method | Sandwich |
| Detection Range | 0.156-10ng/mL |
| Sensitivity | 0.059ng/mL |
| Target | HIF1a |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Hypoxia Inducible Factor 1 Alpha (HIF1a). No significant cross-reactivity or interference between Hypoxia Inducible Factor 1 Alpha (HIF1a) and analogues was observed. |
| Reactivity | Rat |
| Sample Types | Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 100uL standard or sample to each well.Incubate 2 hours at 37℃; 3.Aspirate and add 100uL prepared Detection Reagent A.Incubate 1 hour at 37℃; 4.Aspirate and wash 3 times; 5.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 6.Aspirate and wash 5 times; 7.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 8.Add 50uL Stop Solution.Read at 450nm immediately. |
| Uniprot | O35800 |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | Selective inhibition of PKCβ2 preserves cardiac function after myocardial infarction and is associated with improved angiogenesis of ischemic myocardium in diabetic rats;Effects of adrenomedullin and vascular endothelial growth factor on ischemia/reperfusion injury in skeletal muscle in rats.;Telomeres are elongated in rats exposed to moderate altitude;Effect of combined treatment with rosuvastatin and protein kinase Cβ2 inhibitor on angiogenesis following myocardial infarction in diabetic rats;Maternal omega-3 fatty acid supplementation to a vitamin B 12 deficient diet normalizes angiogenic markers in the pup brain at birth;Metabolomic Analysis of Biochemical Changes in the Plasma of High-Fat Diet and Streptozotocin-Induced Diabetic Rats after Treatment with Isoflavones Extract of Radix Puerariae;Использование гипоксического прекондиционирования для подготовки аутодермотрансплантата у больных со скомпрометированной микроциркуляцией;Telomere elongation protects heart and lung tissue cells from fatal damage in rats exposed to severe hypoxia;Signal Mechanism of the Protective Effect of Combined Preconditioning by Amtizole and Moderate Hypoxia;Expression of Hif-1α, Nf-κb, and Vegf Genes in the Liver and Blood Serum Levels of HIF-1α, Erythropoietin, VEGF, TGF-β, 8-Isoprostane, and Corticosterone in Wistar Rats with High and Low Resistance to Hypoxia. Corticosterone in …;OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth;Age-Specific Features of Hypoxia Tolerance and Intensity of Lipopolysaccharide-Induced Systemic Inflammatory Response in Wistar Rats;Hypoxia Preconditioned Adipose Derived Endothelial Progenitor Cells Promote Bladder Augmentation;ПОТЕНЦИРОВАНИЕ АНТИГИПОКСАНТАМИ ЭФФЕКТА ГИПОКСИЧЕСКОГО ПРЕКОНДИЦИОНИРОВАНИЯ;Maternal omega-3 fatty acids and vitamin E improve placental angiogenesis in late-onset but not early-onset preeclampsia;Short-wave enhances mesenchymal stem cell recruitment in fracture healing by increasing HIF-1 in callus;Prenatal vitamin D supplementation reduces blood pressure and improves placental angiogenesis in an animal model of preeclampsia; |
| Supplier | Cloud Clone |
PROTOCOLS:
SEA798Ra All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
